Get the Stockscreener App
4.68
1.52%
0.07
After Hours:
4.74
0.06
+1.28%
Myriad Genetics Inc stock is traded at $4.68, with a volume of 1.44M.
It is up +1.52% in the last 24 hours and down -2.09% over the past month.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
See More
Previous Close:
$4.61
Open:
$4.7
24h Volume:
1.44M
Relative Volume:
0.91
Market Cap:
$437.62M
Revenue:
$824.50M
Net Income/Loss:
$-365.90M
P/E Ratio:
-1.1839
EPS:
-3.9531
Net Cash Flow:
$-25.60M
1W Performance:
+0.86%
1M Performance:
-2.09%
6M Performance:
-39.69%
1Y Performance:
-51.90%
1-Day Range:
$4.555
$4.82
1-Week Range:
$4.54
$4.88
52-Week Range:
$3.76
$9.875
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.68 | 431.07M | 824.50M | -365.90M | -25.60M | -3.9531 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance UK
Myriad Genetics launches Prequel Prenatal Screen using AMPLIFY technology for early chromosomal risk detection - Traders Union
Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes - Stock Titan
Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes - Stock Titan
Myriad Genetics (MYGN) CFO uses 549 shares for RSU tax withholding - Stock Titan
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P Composite 1500 - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 Health Care - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 1000 - marketscreener.com
Gene Patent Showdown For Myriad Comes to a Head - Yahoo
MYGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Prequel Prenatal Screen enables providers to act on uncertain results, Myriad Genetics asserts - Traders Union
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Myriad Genetics (MYGN) Q4 earnings and revenues surpass estimates - MSN
Myriad Genetics receives FDA approval for ovarian cancer test By Investing.com - Investing.com South Africa
FDA Approves Myriad Genetics' MyChoice CDx Test for Advanced Ova - GuruFocus
Myriad Genetics receives FDA approval for ovarian cancer test - Investing.com
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer - The Manila Times
Portfolio Update: Can Myriad Genetics Inc maintain its current growth rate2026 Trading Volume Trends & Community Driven Trade Alerts - baoquankhu1.vn
Myriad Genetics (MYGN) CTO has shares withheld to cover taxes - Stock Titan
Myriad Genetics (MYGN) CFO granted 206,186 RSUs, 4,752 shares withheld - Stock Titan
Myriad Genetics (MYGN) grants 173196 RSUs, withholds 14683 shares for tax - Stock Titan
Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares - Stock Titan
Myriad Genetics (MYGN) CLO granted 195,876 RSUs and has shares withheld - Stock Titan
Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs - Stock Titan
Myriad Genetics (MYGN) COO receives RSU grant, shares withheld for tax - Stock Titan
Myriad Genetics (MYGN) CEO gets 618,557 RSUs, 47,120 shares withheld - Stock Titan
Myriad Genetics Inc Stock (ISIN: US62855J1043) Eyes Precision Medicine Growth Amid Margin Expansion - AD HOC NEWS
Myriad Genetics, Inc. $MYGN Shares Sold by Anson Funds Management LP - MarketBeat
Market Review: Is now the right time to enter Myriad Genetics Inc2026 Selloffs & Accurate Intraday Trading Signals - baoquankhu1.vn
3 Reasons to Sell MYGN and 1 Stock to Buy Instead - Yahoo Finance
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Myriad Genetics at Leerink Conference: Strategic Moves in Cancer Care By Investing.com - Investing.com Canada
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know - Finviz
Raha, Myriad Genetics CEO, buys $199k in shares By Investing.com - Investing.com South Africa
Insider Buying: Samraat Raha Acquires 40,000 Shares of Myriad Ge - GuruFocus
Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock - MarketBeat
Raha, Myriad Genetics CEO, buys $199k in shares - Investing.com Nigeria
Trading Systems Reacting to (MYGN) Volatility - Stock Traders Daily
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Call Transcript - MSN
Myriad Genetics Q4 2025 earnings preview - MSN
Trading Recap: Whats next for Myriad Genetics Inc stockBreakout Watch & Consistent Return Strategy Ideas - baoquankhu1.vn
Take Profit: What hedge funds are buying Myriad Genetics IncMarket Sentiment Review & Weekly High Momentum Picks - baoquankhu1.vn
Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics, Inc. (MYGN) Competitors - Meyka
Myriad Genetics (NASDAQ: MYGN) files $200M shelf for equity and debt sales - Stock Titan
Myriad Genetics Stock Up on New Breast Cancer MRD Test Launch | 2026News and Statistics - IndexBox
MYGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):